Otsuka : Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia (57KB)
January 19, 2018 at 01:34 am EST
Share
January 19, 2017
For Immediate Release
Company name
Otsuka Holdings Co., Ltd.
Representative
Tatsuo Higuchi
President and Representative Director, CEO
Code number
4578 First Section , Tokyo Stock Exchange
Inquiries
Yuji Kogure
Director, Investors Relations Department
Otsuka Receives Approval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
Otsuka Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets® (generic name is brexpiprazole) in 1mg and 2 mg dosage sizes.
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.
-1-
Otsuka Holdings Co. Ltd. published this content on 19 January 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 January 2018 06:34:01 UTC.
Original documenthttps://www.otsuka.com/en/hd_release/release/pdf.php?news=1725
Public permalinkhttp://www.publicnow.com/view/6CDE0E24690C52D60B391B1ECD084E68663078E5
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
